VCT220 Cut Weight by 9.7% in 16 Weeks. The Titration Data Matter More Than the Pill

The next oral GLP-1 contender has published a result that is difficult to ignore: nearly 10% average weight loss in 16 weeks at its highest dose. The drug is VCT220, also called CX11, and it is not a peptide squeezed into a tablet. It is a once-daily small molecule designed to activate the GLP-1 receptor without an injection or the absorption technology used by oral semaglutide.

That distinction matters, but it is not the most useful part of the new paper. The more revealing finding sits in the safety tables. At the same 160 mg target dose, changing the speed of titration substantially changed the burden of gastrointestinal side effects. The drug’s future may depend as much on how patients reach the dose as on the dose itself.

The news: a peer-reviewed phase II result

Researchers led by Linong Ji of Peking University People’s Hospital reported the randomized phase II trial in Signal Transduction and Targeted Therapy on August 14, 2026. The study enrolled 250 adults at 13 sites in China. Participants had obesity, or overweight with at least one related health condition, but did not have diabetes.

They were assigned to placebo or VCT220 at target doses of 80 mg, 120 mg, or 160 mg once daily. The 160 mg group was split between fast and slow titration schedules. Everyone received lifestyle counseling that targeted a daily 500-calorie deficit, aerobic exercise five times a week, and resistance training twice a week. Treatment lasted 16 weeks, followed by a two-week safety check.

This was a serious efficacy trial, not an open-label before-and-after report. It was randomized, double-blind, placebo-controlled, and registered as NCT06569355. Of the 250 participants, 189 received VCT220 and 61 received placebo. More than 94% completed treatment, which gives the short-term findings a reasonably solid foundation.

The weight-loss signal was fast and dose-dependent

At week 16, average weight change was 5.75% at 80 mg, 7.42% at 120 mg, 9.40% with the slower 160 mg schedule, and 9.73% with the faster 160 mg schedule. Placebo participants lost 1.61%. Every active-dose comparison with placebo met the study’s threshold for statistical significance at p<0.001.

The responder data add useful texture. At least 5% weight loss was achieved by 55.4% of the 80 mg group, 72.6% of the 120 mg group, 77.4% of the fast-titration 160 mg group, and 90.3% of the slow-titration 160 mg group. Only 13.1% of placebo participants reached that mark.

At least 10% weight loss was less common but still notable: the proportions ranged from 4.6% at 80 mg to 45.2% in the fast 160 mg group, versus 1.6% with placebo. Only a small minority reached 15%, and one participant in the fast 160 mg group reached 20% or more. Those details are a useful brake on the headline. A 9.73% group average does not mean every participant lost roughly 10%.

Waist circumference fell by 5.15 to 7.61 centimeters across the VCT220 groups, compared with 1.99 centimeters on placebo. Exploratory measures also moved in a favorable direction, including HbA1c, fasting insulin, triglycerides, total cholesterol, and blood pressure. These secondary signals are encouraging, but the trial was not designed to prove that VCT220 prevents heart attacks, diabetes, or other long-term outcomes.

Oral does not mean side-effect free

The safety profile looked familiar for a GLP-1 receptor agonist. Gastrointestinal events were the main problem, and they became more common as dose increased. GI events occurred in 58.5% of participants at 80 mg, 74.2% at 120 mg, and 72.6% across the pooled 160 mg groups, compared with 27.9% on placebo.

Nausea affected 41.5% to 58.1% of VCT220 participants, depending on dose and schedule, versus 8.2% on placebo. Vomiting ranged from 13.8% to 41.9%, and diarrhea from 17.7% to 29.0%. Most events were mild or moderate and clustered during dose escalation. Two participants permanently stopped VCT220 because of gastrointestinal events.

There were no deaths or drug-related serious adverse events. Five participants experienced nine hypoglycemic episodes across active and placebo groups; all were mild. The investigators reported no important renal, hepatic, gallbladder, psychiatric, or QT-interval safety signal during the short study.

That is reassuring as far as it goes. Sixteen weeks is not long enough to establish chronic safety for a medicine intended to be taken for years. Rare adverse events also do not reliably appear in a 250-person trial.

The titration result deserves more attention

The two 160 mg schedules produced almost the same average weight loss: 9.40% with slower titration and 9.73% with faster titration. Their tolerability was not the same. GI events affected 80.6% of the fast-titration group and 64.5% of the slow-titration group.

That gap came from groups of only 31 participants each, so it should not be treated as a definitive optimization study. Still, it points to a practical lesson already familiar from injectable GLP-1 care: pushing the dose faster may add more nausea and vomiting than useful efficacy. The slow group also had the highest proportion of participants reaching at least 5% weight loss, despite arriving at the target dose later.

A tablet makes administration easier, but it does not repeal receptor pharmacology. VCT220 still activates GLP-1 signaling, which slows gastric emptying, affects appetite, and commonly produces gastrointestinal symptoms. Convenience and tolerability are separate questions.

What makes VCT220 different from oral semaglutide

Oral semaglutide is a peptide drug. Because peptides are readily degraded and poorly absorbed through the gut, its tablet uses an absorption enhancer and comes with strict administration instructions. VCT220 is a nonpeptide small molecule. According to the phase II paper, it does not need specialized delivery technology and was taken with meals, preferably breakfast.

That could simplify daily use. It may also make manufacturing and distribution easier than for a peptide injectable. But “oral” should not be confused with “proven better.” This trial did not compare VCT220 directly with semaglutide, tirzepatide, or orforglipron. Cross-trial comparisons are especially fragile here because study duration, baseline population, dose escalation, and statistical methods differ.

The 16-week curve had not clearly plateaued, which invites speculation about greater loss with longer treatment. It does not guarantee it. Longer studies must show whether weight loss persists, whether side effects remain manageable, and what happens when a broader and older population uses the drug.

What the study cannot tell us

The average participant was 32 years old, had a BMI near 32, and was predominantly Han Chinese. Chinese BMI thresholds were used for enrollment. That makes the study relevant to the population tested, but it limits certainty about performance in more ethnically diverse populations or people with heavier cardiometabolic disease burdens.

The investigators also pooled placebo participants assigned within different dose cohorts. Different titration schedules and site effects can complicate interpretation. Missing primary-endpoint data were handled with multiple imputation under a missing-at-random assumption. Sensitivity analyses supported the main result, but statistical handling cannot replace longer observation.

There is also a financial-interest context. Vincentage Pharma sponsored the trial, and several authors were company employees. Industry funding does not invalidate a randomized study. It does make independent replication, transparent phase III publication, and regulatory review particularly important.

The company has reported positive phase III top-line data in China, and NCT06939296 lists an 840-participant pivotal study. Those sponsor announcements are useful signals, not a substitute for a peer-reviewed phase III paper with full methods and adverse-event tables. VCT220 remains investigational and is not an FDA-approved obesity treatment.

The Oria take

VCT220 has crossed an important line: it now has a peer-reviewed, placebo-controlled human study showing a strong short-term weight-loss signal. This is more substantial than a conference slide or a press release. It also broadens the oral GLP-1 race beyond one or two high-profile drugs.

The right conclusion is narrower than the hype. VCT220 may become a practical once-daily option if longer trials reproduce the efficacy, clarify chronic safety, and find a titration schedule patients can live with. The phase II data make that possibility credible. They do not establish superiority, cardiovascular benefit, or an excuse to use an unapproved product.

For readers watching the field, the next evidence to demand is straightforward: a complete peer-reviewed phase III report, diverse enrollment, at least one year of exposure, discontinuation rates by dose schedule, and eventually head-to-head evidence. Until then, the most honest description is promising, fast, and unfinished.

Sources

• Primary phase II paper: https://www.nature.com/articles/s41392-026-02859-2
• PubMed record (PMID 42595749): https://pubmed.ncbi.nlm.nih.gov/42595749
• Phase II trial registry (NCT06569355): https://clinicaltrials.gov/study/NCT06569355
• Phase III trial registry (NCT06939296): https://clinicaltrials.gov/study/NCT06939296
• Orforglipron phase III comparator context: https://pubmed.ncbi.nlm.nih.gov/40960239

Evidence Grade: B. A randomized, double-blind, placebo-controlled phase II trial provides credible short-term evidence for weight loss and common adverse events. The grade is capped because treatment lasted 16 weeks, the cohort was relatively small and demographically narrow, the sponsor funded the study, and full peer-reviewed phase III evidence is not yet available.

Medical disclaimer

This article is for educational purposes only and is not medical advice. VCT220/CX11 is investigational and is not approved by the U.S. Food and Drug Administration for weight management. Do not buy, use, or dose unapproved GLP-1 products based on early trial results. Decisions about obesity treatment should be made with a licensed clinician using approved medicines, individual risk factors, and appropriate monitoring. Oria exists to help readers distinguish emerging evidence from marketing, not to prescribe treatment.